Quality Investor
About 

Corteva, Inc.

Rank #360Value

CTVA · NYSE · Basic Materials

Corteva, Inc. (CTVA) — Rank #360 by gross profitability (GP/assets 0.20) · ROE 4.3% · Piotroski F-Score 6 / 9.

As-of 2026-09-15 · CIK 0001755672 · all metrics point-in-time as of the filing date.

About

Corteva, Inc. operates in the agriculture business.

Show more

The company operates through two segments, Seed and Crop Protection. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms. It offers trait technologies that enhance resistance to weather, disease, insects, and herbicides used to control weeds, as well as food and nutritional characteristics. This segment also provides digital solutions that assist farmer decision-making with a view to optimize product selection, and maximize yield and profitability. The Crop Protection segment offers products that protect against weeds, insects and other pests, and diseases, as well as enhances crop health above and below ground through nitrogen management and seed-applied technologies. This segment provides herbicides, insecticides, nitrogen stabilizers, and pasture and range management herbicides. It serves agricultural input industry. The company operates in the United States, Canada, Latin America, the Asia Pacific, Europe, the Middle East, and Africa.

The company was founded in 1802 and is headquartered in Indianapolis, Indiana.

Industry
Agricultural Inputs
Sector
Basic Materials
State
DE
Filer Category
Large accelerated filer
Fiscal Year End
December 31

Price History

CTVA+97.0% · +14.5% CAGRSPY+80.5% · +12.5% CAGR

Company Snapshot

P/E and dividend yield are the primary valuation lenses for mature businesses.

Market Cap

$56.00B

P/E (annual)

52.5

P/S (annual)

3.2

P/B

2.2

P/OCF (annual)

16.4

Shareholder Yield

2.9%

Employees

21,500

Industry

Agricultural Inputs

Exchange

NYSE

Signal Flags

4 green
Revenue growth acceleratingGrowth rate increasing year over year
Deferred revenue growingRevenue and deferred revenue both growing — retention signal
RPO outpacing revenueRemaining performance obligations growing faster than recognized revenue — forward demand building
Sequential beat (rev + EPS)Both revenue and EPS exceeded prior quarter — 2-quarter streak

Quality Profile

Profitability

1/1 pass
GP / assets
0.20
Return on equity
4.3%
Gross margin trend
PASS

Safety

1/1 pass
Balance-sheet safety
PASS
Debt / equity
0.64
Current ratio
1.52×
Net cash
-$828.00M

Cash Flow

3/3 pass
Positive FCF
PASS
Cash-backed earnings
PASS
Accruals healthy
PASS
SBC / revenue
—

Growth

2/2 pass
Revenue growth
2.9%
Piotroski F-Score
6 / 9
Share dilution
-2.1%

Terry Smith quality gate

Passes 1/5 Terry Smith thresholds

3 of 5 thresholds not computable from filed data.

What Growth Is Priced In

Implied revenue growth (10Y)

7.9%

incredible deal

The annual FCF growth rate today's price requires over a 10-year horizon (discount rate 10%, terminal growth 2.5%).

Buyback tailwind: -2.1% — per-share value needs a total required return of 5.8% once share-count change is priced in.

vs. own 6-year median revenue growth: 2.8%

priced above its own history

Cost-of-equity sensitivity (implied growth at different discount rates)

r = 8%

3.6%

r = 10% (base)

7.9%

r = 12%

11.7%

Net debt / market cap: 1.4%

Base FCF: $2.8B3Y mean FCF: $1.8B

Valuation History

Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.

P / E

Price / diluted EPS

46.3xFair
21.5xmed 47.1x51.7x

P / S

Price / revenue per share

2.9xExpensive
1.6xmed 2.4x2.9x

P / B

Price / book value per share

2.1xExpensive
0.3xmed 1.5x2.1x

P / GP

Price / gross profit per share

6.1xExpensive
4.4xmed 5.8x6.5x

P / FCF

Price / free cash flow per share

17.9xCheap
17.5xmed 24.7x169.9x

Dividend yield and payout ratio are the primary reads at this stage (trailing P/E — see valuation above).

Profitability

Gross profitability (GP / assets)

0.20

Primary signal (Novy-Marx).

Return on equity

4.3%

Gross margin

47.3%

Revenue growth (YoY)

2.9%

RPO growth (YoY)

7.9%

Remaining performance obligations growth — RPO > revenue = forward demand building.

Gross margin improving

Margin trend vs prior year.

PASS

Operating Leverage

2022202320242025
Revenue vs COGS
Revenue vs OpEx
Op. Income vs Revenue

Growth

Revenue CAGR (3Y)

-0.1%

Revenue CAGR (5Y)

4.1%

Earnings CAGR (3Y)

-1.6%

FCF CAGR (3Y)

119.3%

Anti-fragile safety

Balance-sheet safety

Composite anti-fragile check.

PASS

Debt / equity

0.64

Current ratio

1.52×

Quick ratio

0.76×

Net cash

-$828.00M

Cash & equivalents minus total debt.

Cash-flow health

Free cash flow

$2.81B

Operating cash flow minus capex.

Positive free cash flow

PASS

FCF / net income

1.57

Cash-backing of earnings.

FCF/NI divergence

Unfavorable divergence (yellow flag).

PASS

Accruals healthy

Cash-backed earnings.

PASS

SBC / revenue

—

Stock-based comp intensity.

Dividend safety

Composite score

3.2 / 5

Good
Payout ratio
43.4%4/5 Strong
FCF coverage
5.93×5/5 Strong
Dividend growth streak
4 yr2/5 Fair
Balance-sheet health
D/E 0.64 · IC N/A2/5 Fair

Piotroski F-Score

F-Score

6 / 9

Fundamental-strength score (0-9).

Lifecycle Phase History

20202025
Value
Capital Return
View full financial statements →